MetaCap

Amphastar Pharmaceuticals (AMPH) vs LB Pharmaceuticals (LBRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

LB Pharmaceuticals (LBRX) has outperformed Amphastar Pharmaceuticals (AMPH) over the past year, gaining 153.4% versus a gain of 8.6%. LB Pharmaceuticals is the larger company by market cap ($1.26 billion vs $1.20 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMPH+8.61%LBRX+153.42%
+236%+94%-48%
Nov 21, 20251 yearNov 20, 2026
AMPH+0.68%LBRX+131.25%
+205%+77%-52%
Sep 8, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMPH versus LBRX key metrics
MetricAMPHLBRX
Share price$28.25$38.85
Market cap$1.20B$1.26B
1-day change+0.50%-2.97%
YTD return+5.49%+74.53%
1-year return+8.61%+153.42%
5-year return+41.89%—
P/E ratio (TTM)12.96—
Forward P/E8.43—
EPS (TTM)$2.18$-1.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$719.89M—
Revenue growth (YoY)-1.65%—
Net income (latest FY)$98.09M$-25.20M
Gross margin49.46%—
Operating margin19.50%—
Net margin13.63%—
52-week high$31.00$50.16
52-week low$16.65$15.55
Distance from 52-week high-8.87%-22.55%
Analyst consensusholdstrong_buy
Avg. price target upside-13.27%+49.29%
Average volume475.35K373.16K
Shares outstanding42.65M32.36M
Employees1,97662
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LBRX has outperformed AMPH by 144.8 percentage points over the past year.

About Amphastar Pharmaceuticals

AMPH stock →

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees

About LB Pharmaceuticals

LBRX stock →

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.

Health Care · Biotechnology: Pharmaceutical Preparations · 62 employees

AMPH vs LBRX FAQ

Which is bigger, Amphastar Pharmaceuticals or LB Pharmaceuticals?

LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.26B compared with $1.20B for Amphastar Pharmaceuticals (AMPH).

Which stock has performed better over the past year, AMPH or LBRX?

LBRX returned +153.42% over the past 12 months, compared with +8.61% for AMPH (price return, excluding dividends). Past performance does not predict future results.

Are Amphastar Pharmaceuticals and LB Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons